Skip to content

Novel NRTI elvucitabine active against HIV in a 7-day monotherapy study

Boosted fosamprenavir and atazanavir show comparable potency, tolerability in treatment-naive

Antibody to CCR5 receptor safe, effective, suitable for weekly dosing, preliminary study shows

Trizivir non-inferior to unboosted atazanavir in treatment-naive

Treatment of acute hepatitis C produces good response rates in HIV-positive patients

HIV/HCV co-infected patients respond to re-treatment with pegylated interferon plus ribavirin

16% of drug-naive entering GSK US studies already have resistance

Nevirapine hepatotoxicity after treatment switch no more likely at higher CD4 counts

Suspected abacavir hypersensitivity less likely to be diagnosed in people of African ethnicity